Abstract

Despite advances in precision medicine for non-small cell lung cancer (NSCLC), biomarker testing for these therapies remain frequently underutilized, delayed, and inequitable. Pulmonologists often play a critical role in the initial diagnostic steps for patients with lung cancer and previous data show variability in their knowledge and practices regarding biomarker testing. The purpose of this study is to better understand how pulmonologists' view their role in lung cancer care.